No responses to oral etoposide in 15 patients with recurrent brain tumors

Medical and Pediatric Oncology

Volumn 35, Issue 1, 2000, Pages 80-82

  Korones, David N ^a,e   Fisher, Paul G ^b   Cohen, Kenneth J ^c   Dubowy, Ronald L ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e Golisano Childrens Hospital at Strong   (United States)

Author keywords

Brain tumor; Childhood cancer; Oral etoposide; Recurrence; VP 16

Indexed keywords

ETOPOSIDE;

ADOLESCENT; ADULT; BRAIN TUMOR; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUTROPENIA; PRIORITY JOURNAL; SURVIVAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 0033948229     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-911X(200007)35:1<80::AID-MPO15>3.0.CO;2-Z     Document Type: Conference Paper

References (21)

1. Martin M. Lluch A. Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994;12:986-991.
2. Waits TM. Johnson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 1992:10:292-296.
3. Edmunds PM and Slevins ML. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994;69:191-195.
4. Hainsworth JD. Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma. Leukemia Lymphoma 1993;10 Suppl:65-72.
5. Einhorn LH. Daily oral etoposide in the treatment of cancer. Semin Oncol 1991;18(Suppl 2):43-47.
6. Mathew P, Ribeiro RC, Sonnichsen D. et al. Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol 1994;12:1452-1457.
7. Simon A, Nagel D, Kitchen BJ, and Bode U. Clinical relevaence of etoposide (VP-16) pharmacokinetics in children and adults. Int J Pediatr Hematol Oncol 1997;4:401-414.
8. Relling MV, Mahmoud HH. Pui C, et al. Etoposide achieves potentially cytotoxic concentrations in the CSF of children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:399-404.
9. Kiya K, Uozumi T, Ogasawara H, et al. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol 1992;29:339-342.
10. Tirelli U, Carbone A, Crivellari D, et al. Etoposide (VP-16-213) in malignant brain tumors: a phase II study. J Clin Oncol 1984;2: 432-437.
11. Chamberlain MC. Recurrent brainstem gliomas treated with oral VP-16. J Neurooncol 1993;15:133-139.
12. Chamberlain MC and Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995;13:2072-2076.
13. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP-16) for patients with recurrent malignant glioma. J Neurooncol 1996;27:14955.
14. Ashley DM, Meier L, Kerby T, Zalduondo FM. et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996;14:1922-1927.
15. Needle MN, Molloy PT, Geyer JR, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 1997;29:28-32.
16. Chamberlain MC. Recurrent cerebellar gliomas: salvage therapy with oral etoposide. J Child Neurol 1997;12:200-204.
17. Chamberlain MC. Recurrent supratentorial malignant gliomas in children. Arch Neurol 1997;54:554-558.
18. Common Toxicity Criteria. Version 2.0. Bethesda, MD: National Institute of Health, National Cancer Institute.
19. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13:346-353.
20. Lee E. Statistical methods for survival data analysis, 2nd ed. New York: John Wiley and Sons; 1992.
21. Slevin MI, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-1340.